Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies Influencing My Practice Following EACS 2021—Audio Recap

October 27-30, 2021; London, United Kingdom
Listen to expert insights from Tristan J. Barber, MA, MD, FRCP, on some of the most clinically relevant new data presented at EACS 2021, including first-line, switch, and long-acting ART, the efficacy of COVID-19 vaccinations in PWH, and more.
Tristan J. Barber, MA, MD, FRCP
Released: November 30, 2021

In this episode, Tristan J. Barber, MA, MD, FRCP, discusses new HIV data from EACS 2021, including:

  • First-line therapies
    • BIC/FTC/TAF in a test-and-treat model in IMEA 055 FAST
    • Week 144 data of ISL + DOR in treatment-naive patients from P011
  • Switch Strategies
    • Data on the use of DTG/3TC in patients with an M184V mutation from SOLAR 3D and the French Dat’AIDS Cohort
  • Long-Acting Therapies
    • Efficacy and safety of LA CAB + RPV by BMI
    • Long-term follow-up of participants who discontinued LA CAB + RPV in the ATLAS, ATLAS-2M, and FLAIR trials
    • Patient satisfaction with LA CAB + RPV from the CARISEL study
    • Resistance and subgroup data from the CAPELLA study of lenacapavir in heavily treatment–experienced patients
  • COVID-19 vaccination efficacy and the impact of the pandemic on viral suppression in PWH

Information on this Educational Activity

Faculty

Tristan J. Barber, MA, MD, FRCP

Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom

Tristan J. Barber, MA, MD, FRCP, has disclosed that he has received funds for research support from Roche; consulting fees from Gilead Sciences, MSD, Theratechnologies, and ViiV; fees for non-CME/CE services from Gilead Sciences, MSD, and ViiV; and other financial or material support from Gilead Sciences and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Released: November 30, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 30, 2022

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Released: November 29, 2022

Review the latest data on ART safety and tolerability in special populations in this slideset, from Clinical Care Options (CCO)

Jean Rene Anderson, MD Jill Blumenthal, MD, MAS Marta Boffito, MD, PhD, FRCP Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Joseph J. Eron, Jr., MD Julian Falutz, MD, FRCPC Eric K. Farmer, PharmD, BCPS, AAHIVP Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc William R. Short, MD, MPH, AAHIVS Darcy Wooten, MD Released: November 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings